New research uncovers major issue with tsunami warning systems: 'It's not a matter of if, but when'
Tsunami warning systems have seen significant advancements with the development of new technologies. However, there seem to be limitations in these systems.
Researchers from the University of Western Ontario found that machine learning and advanced decision-making tools could improve how quickly and accurately warnings are issued.
The study, published in the Coastal Engineering Journal, suggests that more advanced artificial intelligence models can improve tsunami warnings — provided they're trained on high-quality, real-world data.
The researchers built tsunami warning models using three different methods: multiple linear regression, random forest, and neural network. The last two methods worked better, but the quality of data used to train the models made a significant difference in the accuracy of their predictions.
If the training data doesn't reflect real-world conditions, the model may not perform accurately even if it ran well during standard tests. And that's the key challenge. Not all tsunami-prone areas have real-world data. For instance, there are only four ocean-bottom sensors on the west coast of Canada.
In Tofino, a popular surfing destination on Vancouver Island, this lack of data poses a huge problem in predicting tsunamis. Although no tsunami has ever hit the town, its topography puts it at a high risk for a huge tsunami.
Beneath the waters near Tofino is a tectonic plate boundary whose movement can produce a magnitude 9.0 earthquake. One big jolt from the Cascadia Subduction Zone could trigger a tsunami up to 30 meters high, capable of reaching the shoreline within 20 minutes.
The researchers still don't know how large the tsunami might be, but they're certain that it will happen. "It's not a matter of if, but when," said Katsu Goda, a University of Western Ontario associate professor and Canada Research Chair in multi-hazard risk assessment, per Phys.org.
Around the globe, researchers are doubling down on technology that can help predict and mitigate the impact of natural disasters.
One team has developed a new model to improve the predictions of tsunamis and help address deadly storm surges. Another is developing a futuristic, self-powered seawall that protects against tsunami waves and transforms tidal water movement into electricity.
Do you think our power grid needs to be upgraded?
Definitely
Only in some states
Not really
I'm not sure
Click your choice to see results and speak your mind.
Researchers are also developing artificial intelligence-powered flood vision to predict how flooding from rising seas and severe storms could impact local communities, helping people visualize risks and prepare in advance before the impacts of nature become severe.
There's still too much uncertainty involved in predicting tsunamis, but these developments represent important progress toward more accurate warning systems that can give people more time to evacuate, save lives, and protect infrastructure and ecosystems.
In the meantime, staying informed on critical climate issues can help boost awareness and preparedness for calamities.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Scientists raise red flag over effects of microscopic threat to vital organs: 'A potential health risk'
Scientists raise red flag over effects of microscopic threat to vital organs: 'A potential health risk' A new study on mice has highlighted the damage that ingested microplastics can cause to different organs. What's happening? Researchers assessed the toxicity of polystyrene microplastics to the gut and mammary glands in subject mice, according to the study, published in the journal Science of Food. The scientists found that the tiny plastic particles accumulated in various tissues, causing significant harm to the gut and mammary glands. Specifically, they found that microplastics could "disrupt the intestinal barrier" and lead to inflammation of the colon and an imbalance of the gut microbiome. They also observed that microplastics can accumulate in mammary tissue, causing inflammatory damage there, among other effects. "These findings indicate that ingestion of microplastics poses a potential health risk," the authors stated. "Further control of microplastics contamination in food is needed to promote public health and wellness." Why are microplastics concerning? The study added to a growing understanding and body of research about the health impacts of microplastics. For instance, a previous experiment on pigs discovered that microplastic exposure can trigger an inflammatory response in the enteric nervous system, which affects functions including immune responses. The effects of microplastics on human health are still being explored. But other studies have linked microplastic exposure to health problems such as cancer, dementia, and impaired blood flow in the brain. What's being done about microplastics? Though microplastics pollute soil, water, food, and air, scientists are discovering new ways to remove them from our environment. For instance, one team found a way to get them out of soil by using a type of processed farm waste. You can help reduce the amount of microplastics entering the environment, and reduce your own exposure, by opting for plastic-free alternatives to everyday products. Choose reusable bottles and containers instead of single-use varieties, for instance. Do you worry about having toxic forever chemicals in your home? Majorly Sometimes Not really I don't know enough about them Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Zero Candida Technologies to Present at the OTCQB Venture Virtual Investor Conference on August 7th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a medical device company developing a SMART, AI-driven FemTech device to revolutionize women's health, today announced that Sophya Galper Komet, CFO, and Dr. Asher Holzer, Founder, will present live at the OTCQB Venture Virtual Investor Conference hosted by on August 7th , 2025. DATE: August 7th TIME: 12:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: August 7 & 8, 2025 This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Company Highlights Demonstrated 99.999% Candida elimination in 3 hours during POC testing, targeting FDA De Novo regulatory pathway Expanding global IP portfolio with patents filed in Europe, the United States, Brazil, and fully granted in South Africa Cross-listed on FSE and OTCQB, including recent DTC eligibility, broadening investor access In active discussions with major hospitals and U.S. pharmaceutical companies to support future clinical trials and commercialization About Zero Candida Technologies Zero Candida Technologies, Inc. is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women's health. The Company is developing a SMART, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. This condition affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. With the VVC treatment market projected to exceed US $2B by 2030, Zero Candida is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century. To learn more, visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Zero Candida Technologies, Inc.+1 (647) 874-3767 investors@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@


Medscape
2 hours ago
- Medscape
Neuropathy Risk Influenced By Racial, Ethnic Disparities
TOPLINE: Known risk factors for peripheral neuropathy (PN) may explain the higher prevalence of the condition in non-Hispanic Black adults but not in Hispanic adults in the US, a new study showed. Researchers found that other factors may drive the disparity, including social determinants of health, such as food insecurity and a high percentage of total caloric intake from saturated fatty acids. METHODOLOGY: This cross-sectional secondary analysis included more than 8000 US adults (mean age, 61 years; 50% women) who participated in the National Health and Nutrition Examination Survey during 1999-2004. 55% of total participants were non-Hispanic White, 18% were non-Hispanic Black, 24% were Hispanic individuals, and 3% were of other races/ethnicities. Researchers assessed PN using a monofilament test for reduced sensation in both feet at three plantar locations: first metatarsal head, fifth metatarsal head, and the hallux. Demographic (age, sex, and race/ethnicity), metabolic (height, weight, waist circumference, systolic and diastolic blood pressure, and levels of high- and low-density lipoprotein cholesterol and A1c), and lifestyle (physical activity and diet) risk factors, as well as social determinants of health (food security, household income, and health insurance), were evaluated. TAKEAWAY: Higher age- and sex-adjusted odds of PN were observed in both Black (odds ratio [OR], 1.39) and Hispanic (OR, 1.31) participants than in White participants. Additionally, men had a higher risk for PN than women after age and race adjustment — but not after comprehensive adjustment. After adjusting for metabolic, lifestyle, and social determinants of health factors, Hispanic individuals maintained a higher likelihood of PN than White individuals (OR, 1.32; P = .001), while Black and White individuals had similar odds of PN (OR, 1.17; P = .17). Lack of health insurance (OR, 1.49), older age (OR, 1.05), taller height (OR, 1.03), higher levels of A1c (OR, 1.13), and larger waist circumference (OR, 1.01) were all associated with an increased risk for PN. Among Hispanic individuals specifically, food insecurity (OR, 1.48) and increased percentage of total caloric intake from saturated fatty acids (OR, 1.06) were linked to increased PN risk. IN PRACTICE: 'After comprehensively adjusting for known risk factors, we found that Black people had similar odds of neuropathy compared to White people, whereas Hispanic people continued to be at an increased likelihood of having neuropathy. Therefore, it is likely that unknown social risk factors exist for this population,' lead study author Evan Lee Reynolds, PhD, Michigan State University, East Lansing, Michigan, said in a press release. Authors of an accompanying editorial added that the findings 'are a call to action to continue to address the disproportionate exposure to modifiable risk factors in Black and Hispanic populations.' SOURCE: The study and the accompanying editorial were published online on July 16 in Neurology. The editorial was authored by Georgette Dib and Nicholas E. Johnson, Virginia Commonwealth University, Richmond, Virginia. LIMITATIONS: The study was retrospective, cross-sectional, and partly exploratory in nature and relied on self-reported data. Additionally, some data were missing, monofilament testing may have led to misclassification of PN, and assessment of triglyceride levels was performed only in 53% of participants. Study findings were not generalizable to other racial/ethnic groups or individuals with multiple races/ethnicities. DISCLOSURES: Several investigators reported receiving funding from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, Andrea and Lawrence A. Wolfe Research Professorship, Robert E. Nederlander Sr. Program for Alzheimer's Research, Andrea and Lawrence A. Wolfe Brain Health Initiative Fund, A. Alfred Taubman Medical Research Institute, and the NeuroNetwork for Emerging Therapies. One investigator also reported consulting for DynaMed, receiving research and editorial support from the American Academy of Neurology, and providing medicolegal consultations. One of the editorialists reported having various ties with various sources, including pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.